

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

No.: 13/2025/CV-MED

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, March 26, 2025

To : - **State Securities Commission**
 - **Hanoi Stock Exchange**

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Address: 358 Giai Phong, Phuong Liet Ward, Thanh Xuan District, Hanoi

Tax code: 0100108430

Information disclosure person: Mai Nhat Thanh

Position: General Director

Pursuant to Circular No. 96/2020/TT-BTC of the Ministry of Finance on periodic information disclosure of organizations, specific explanations are provided for cases where after-tax profits differ by 10% compared to the same period last year.

Mediplantex National Pharmaceutical Joint Stock Company explains the audited financial statements of 2024 as follows:

- Net revenue from sales and service rendering in 2024 was VND 443,135,811,734, increased by 10%. Gross profit from sales was VND 92,561,395,080, increased 11% compared to 2023.

- Financial revenue was VND 2,194,907,734, decreased 72% compared to the same period last year due to the company paying money to partners. Interest expense was VND 3,787,313,457, declined 30% because of effective debt management policy and reduced average loan balance in the year compared to 2023.

- Sales expense was VND 7,956,365,486, down 37% compared to the same period last year. Management expense was VND 62,411,577,931 increased by 11%. Therefore, Net profit from business activities reached 18,505,896,390 VND increased by 21% compared to the same period last year.

- In addition, in 2024, there was a high increase in Other income of VND 1,194,147,025 and Other profit, which was VND 912,211,504 increased by 329% compared to the same period last year.

- From the above factors, the profit after corporate income tax was VND 15,246,766,212 increased by 30% compared to the same period in 2023.

Above is the explanation of Mediplantex National Pharmaceutical Joint Stock Company reporting to the State Securities Commission and Hanoi Stock Exchange on the change of indicators in the financial statements of 2024 compared to the financial statements of the same period last year of Mediplantex National Pharmaceutical Joint Stock Company.

Best regards!

Recipient:

- *As above*
- *Admin*

MEDIPLANTEX NATIONAL PHARMACEUTICAL .,JSC
GENERAL DIRECTOR



Mai Nhat Thanh